In a new study, researchers from UCL Cancer Institute have found that a subset of immune cells are capable of killing cancer cells when they are activated. This could lay the foundation stone for effective anti-cancer therapies believe the researchers.
The study titled, “Regulatory T cells restrain Interleukin-2 and Blimp-1-Dependent acquisition of cytotoxic function by CD4+ T cells” was published in the latest issue of the journal Immunity on the 7th of January 2020.
